Intra Cellular Therapies Presents Preclinical Data From Schizophrenia And Sleep Maintenance Programs

Intra-Cellular Therapies, Inc. (ITI) presented preclinical data on ITI-007, its first in class dual 5HT2A receptor antagonist/dopamine receptor phosphoprotein modulator (DPPM) at a major medical meeting last week. The Company is developing ITI-007 for the treatment of schizophrenia and other related psychiatric conditions. In this presentation, ITI-007 was shown to possess a unique pharmacologic profile, unlike any other existing antipsychotic drug. [click link for full article]

More: continued here

Filed under: Clinical Trials on December 20th, 2007